Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.
Opthea Limited (ASX: OPT) generates frequent news as a clinical-stage biopharmaceutical company developing therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Company announcements describe the progress of its lead product candidate, sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor studied in combination with standard-of-care anti-VEGF-A therapies.
News items for OPT commonly cover clinical milestones, including Phase 2b and Phase 3 trial updates in wet AMD, early-stage data in DME, and presentations of trial results and subgroup analyses at scientific meetings and in peer-reviewed journals. Opthea also releases updates on manufacturing activities, such as completion of drug substance and drug product Process Performance Qualification campaigns to support potential regulatory filings.
Investors following OPT news will also see corporate and capital markets developments. These include half-year financial reports, cash runway commentary, capital raising outcomes, and details of a Development Funding Agreement and its subsequent settlement. The company has reported that primary endpoints were not met in its COAST and ShORe Phase 3 wet AMD trials and has described the decision, together with its DFA investors, to discontinue development of sozinibercept in wet AMD, along with workforce reductions, management changes, and a planned strategic review.
Regulatory and listing updates also appear in Opthea’s news flow, such as announcements related to its intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market. For readers interested in the intersection of ophthalmology, clinical trial data, and biotech corporate strategy, the OPT news feed provides ongoing context on Opthea’s programs and corporate actions.
Opthea Limited (ASX:OPT; Nasdaq:OPT) has received an initial Pediatric Study Plan (iPSP) waiver from the FDA for OPT-302, its leading candidate for wet age-related macular degeneration treatment. This waiver eliminates the need for additional pediatric studies, streamlining the pathway to a marketing application. CEO Dr. Megan Baldwin highlighted this milestone as vital for ongoing Phase 3 trials in adults, aiming for potential regulatory approval. The company focuses on unmet needs in retinal diseases, combining OPT-302 with anti-VEGF-A therapies for improved efficacy.
Opthea Limited has announced the treatment of the first patient in its Phase 3 pivotal studies for OPT-302, targeting treatment-naïve wet age-related macular degeneration (AMD). Conducting two global trials (ShORe and COAST), Opthea aims to assess the efficacy of OPT-302 combined with anti-VEGF-A therapies compared to monotherapy. The ShORe trial involves 990 patients, focusing on improving visual acuity over 52 weeks. The promising results from the Phase 2b trial, showing significant visual gains, support this new phase. Top-line data is expected in 2023, paving the way for potential FDA and EMA applications.
Opthea Limited (ASX:OPT, Nasdaq:OPT) announces a virtual presentation by CEO Dr. Megan Baldwin at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 3:50 PM ET. The presentation will focus on their leading product candidate, OPT-302, designed to treat retinal diseases like wet age-related macular degeneration and diabetic macular edema. The live webcast will be available on Opthea’s website. The company acknowledges inherent risks in biotechnology investments due to the complex nature of drug development and regulatory approval processes.
Opthea Limited (ASX:OPT; Nasdaq: OPT) has finalized the designs for two pivotal Phase 3 clinical trials, ShORe and COAST, to assess its drug OPT-302 for treating wet age-related macular degeneration (AMD). Both trials will evaluate OPT-302 in combination with Lucentis® and Eylea®, involving approximately 990 treatment-naive patients each. Initiation is on track for Q1 2021, with top-line data expected in late 2023. Successful outcomes may lead to marketing approvals in the US and EU, potentially tapping into the $11.9 billion market for retinal diseases.
Opthea Limited (ASX:OPT, Nasdaq: OPT) announced that CEO Dr. Megan Baldwin will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference on Feb 24, 2021, at 3:40pm ET. The presentation will focus on Opthea's novel therapy for retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema. A live webcast will be accessible via their Investors page. Investors are cautioned about the inherent risks in biotechnology investments, including lengthy clinical trials and regulatory approvals.
Opthea Limited (ASX:OPT, Nasdaq: OPT) announced the pricing of its initial public offering in the U.S., offering 8,563,300 American Depositary Shares (ADS) at $13.50 each. The offering aims to raise approximately $128.2 million in gross proceeds. Additionally, the company offered pre-funded warrants for 936,700 ADSs at an effective price of $13.49999 per warrant. An option for underwriters to purchase an additional 1,425,000 ADSs exists. The ADSs are expected to begin trading on October 16, 2020, with the offering closing on or around October 20, 2020.